<p>Corvus Pharmaceuticals, Inc.（纳斯达克代码：CRVS - 免费报告）- HC Wainwright 的研究分析师在 8 月 11 日星期一向投资者发布的研究报告中提高了对 Corvus Pharmaceuticals 2025 年第三季度每股收益的预期。HC Wainwright 的分析师 S. Lee 现在预计该公司本季度每股收益为（$0.14），高于之前的预期（$0.15）。市场普遍预计 Corvus Pharmaceuticals 当前全年的每股收益为（$0.63）。HC Wainwright 还对 Corvus Pharmaceuticals 2025 年第四季度的每股收益预期为（$0.14），2025 财年的每股收益预期为（$0.51），2026 年第一季度的每股收益预期为（$0.12），2026 年第二季度的每股收益预期为（$0.12），2026 年第四季度的每股收益预期为（$0.13），2026 财年的每股收益预期为（$0.50）以及 2027 财年的每股收益预期为（$0.40）。</p>
<p>其他几位股票研究分析师最近也对该公司发布了报告。瑞穗证券在 5 月 20 日星期二对 Corvus Pharmaceuticals 设定了 11.00 美元的目标价，并给予该股票 “跑赢大盘” 的评级。Oppenheimer 在 5 月 9 日星期五重申了 “跑赢大盘” 的评级，并将 Corvus Pharmaceuticals 的目标价从 15.00 美元上调至 17.00 美元。最后，华尔街 Zen 在 8 月 9 日星期六将 Corvus Pharmaceuticals 的评级从 “卖出” 上调至 “持有”。一位股票研究分析师给予该股票 “持有” 评级，四位分析师给予该股票 “买入” 评级。根据 MarketBeat 的数据，Corvus Pharmaceuticals 目前的平均评级为 “适度买入”，共识目标价为 15.00 美元。</p>
<p>获取 <strong>Corvus Pharmaceuticals</strong> 警报：</p>
<p><strong>查看我们关于 CRVS 的最新研究报告</strong></p>
<h2>Corvus Pharmaceuticals 股价上涨 11.1%</h2>
<p>Corvus Pharmaceuticals 的股票在星期四以 5.00 美元开盘。该股票的 50 日移动平均价格为 4.21 美元，200 日移动平均价格为 4.05 美元。该公司的市值为 3.7255 亿美元，市盈率为 -4.95，贝塔值为 0.42。Corvus Pharmaceuticals 的一年低点为 2.54 美元，一年高点为 10.00 美元。</p>
<p>Corvus Pharmaceuticals（纳斯达克代码：CRVS - 获取免费报告）最近在 8 月 7 日星期四公布了季度收益数据。该公司报告的每股收益（EPS）为（$0.10），超过了市场普遍预期的（$0.13）3 美分。</p>
<h2>Corvus Pharmaceuticals 的内部买卖</h2>
<p>在其他新闻中，董事 Peter A. Thompson 于 6 月 27 日星期五出售了 1,176,332 股该公司的股票。该股票以平均价格 4.16 美元出售，总交易额为 4,893,541.12 美元。出售完成后，该董事直接持有该公司 7,165,006 股股票，价值 29,806,424.96 美元。此交易代表其持股减少了 14.10%。该交易已在向证券交易委员会提交的文件中披露，文件可在此链接查看。28.50% 的股票由公司内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>一些对冲基金最近对 CRVS 的持仓进行了调整。Sowell Financial Services LLC 在第一季度以约 38,000 美元的价格收购了 Corvus Pharmaceuticals 的新股份。Virtus ETF Advisers LLC 在第四季度以约 47,000 美元的价格收购了 Corvus Pharmaceuticals 的新股份。新泽西州警察和消防员退休系统在第二季度以约 49,000 美元的价格收购了 Corvus Pharmaceuticals 的新股份。ProShare Advisors LLC 在第二季度以约 54,000 美元的价格收购了 Corvus Pharmaceuticals 的新股份。最后，Alpine Global Management LLC 在第四季度以约 62,000 美元的价格收购了 Corvus Pharmaceuticals 的新股份。机构投资者和对冲基金持有该公司 46.64% 的股票。</p>
<h2>Corvus Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Corvus Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司，专注于开发和商业化免疫调节剂产品候选药物，以治疗实体癌症、T 细胞淋巴瘤、自身免疫、过敏和传染病。其主要产品候选药物是 soquelitinib（CPI-818），这是一种选择性共价抑制剂，针对白细胞介素 2 诱导的 T 细胞激酶（ITK），目前正在进行多中心的 1/1b 期临床试验，以治疗外周 T 细胞淋巴瘤、实体肿瘤和特应性皮炎。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 Corvus Pharmaceuticals</li>
<li>TSX 风险投资交易所（前称加拿大风险投资交易所）</li>
<li>数据中心为这三只核能股票创造了牛市案例</li>
<li>制造业股票投资</li>
<li>特斯拉的旗帜刚刚断裂：这对股票意味着什么</li>
<li>房地产投资信托是否值得在您的投资组合中占有一席之地？</li>
<li>三家公司将从特朗普的半导体关税中获利</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 Corvus Pharmaceuticals 吗？</h2>
<p>在您考虑投资 Corvus Pharmaceuticals 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Corvus Pharmaceuticals 并不在名单上。</p>
<p>虽然 Corvus Pharmaceuticals 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Corvus制药

<p>HC Wainwright 将 Corvus Pharmaceuticals (NASDAQ:CRVS) 2025 年第三季度每股收益预期从（$0.15）上调至（$0.14）。全年共识预期为每股（$0.63）。其他分析师的目标价范围在 $11.00 到 $17.00 之间，平均评级为 “适度买入”，共识目标价为 $15.00。Corvus Pharmaceuticals 的股票开盘价为 $5.00，市值为 3.7255 亿美元。该公司上个季度报告的每股收益为（$0.10），超出预期。内部交易显示董事持股减少了 14.10%</p>

<p>Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Research analysts at HC Wainwright boosted their Q3 2025 earnings per share estimates for shares of Corvus Pharmaceuticals in a research note issued to investors on Monday, August 11th. HC Wainwright analyst S. Lee now anticipates that the company will earn ($0.14) per share for the quarter, up from their previous estimate of ($0.15). The consensus estimate for Corvus Pharmaceuticals' current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals' Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.51) EPS, Q1 2026 earnings at ($0.12) EPS, Q2 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.50) EPS and FY2027 earnings at ($0.40) EPS.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals, Inc.（纳斯达克代码：CRVS - 免费报告）- HC Wainwright 的研究分析师在 8 月 11 日星期一向投资者发布的研究报告中提高了对 Corvus Pharmaceuticals 2025 年第三季度每股收益的预期。HC Wainwright 的分析师 S. Lee 现在预计该公司本季度每股收益为（$0.14），高于之前的预期（$0.15）。市场普遍预计 Corvus Pharmaceuticals 当前全年的每股收益为（$0.63）。HC Wainwright 还对 Corvus Pharmaceuticals 2025 年第四季度的每股收益预期为（$0.14），2025 财年的每股收益预期为（$0.51），2026 年第一季度的每股收益预期为（$0.12），2026 年第二季度的每股收益预期为（$0.12），2026 年第四季度的每股收益预期为（$0.13），2026 财年的每股收益预期为（$0.50）以及 2027 财年的每股收益预期为（$0.40）。</p>
</div><p>Several other equities research analysts also recently issued reports on the company. Mizuho set a $11.00 price objective on Corvus Pharmaceuticals and gave the stock an &#34;outperform&#34; rating in a research note on Tuesday, May 20th. Oppenheimer reaffirmed an &#34;outperform&#34; rating and set a $17.00 price target (up from $15.00) on shares of Corvus Pharmaceuticals in a research note on Friday, May 9th. Finally, Wall Street Zen raised Corvus Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, August 9th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Corvus Pharmaceuticals presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $15.00.</p>
<div class="lb-trans"><p>其他几位股票研究分析师最近也对该公司发布了报告。瑞穗证券在 5 月 20 日星期二对 Corvus Pharmaceuticals 设定了 11.00 美元的目标价，并给予该股票 “跑赢大盘” 的评级。Oppenheimer 在 5 月 9 日星期五重申了 “跑赢大盘” 的评级，并将 Corvus Pharmaceuticals 的目标价从 15.00 美元上调至 17.00 美元。最后，华尔街 Zen 在 8 月 9 日星期六将 Corvus Pharmaceuticals 的评级从 “卖出” 上调至 “持有”。一位股票研究分析师给予该股票 “持有” 评级，四位分析师给予该股票 “买入” 评级。根据 MarketBeat 的数据，Corvus Pharmaceuticals 目前的平均评级为 “适度买入”，共识目标价为 15.00 美元。</p>
</div><p>Get <strong>Corvus Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Corvus Pharmaceuticals</strong> 警报：</p>
</div><p><strong>View Our Latest Research Report on CRVS</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 CRVS 的最新研究报告</strong></p>
</div><h2>Corvus Pharmaceuticals Trading Up 11.1%</h2>
<div class="lb-trans"><h2>Corvus Pharmaceuticals 股价上涨 11.1%</h2>
</div><p>Shares of Corvus Pharmaceuticals stock opened at $5.00 on Thursday. The stock has a 50-day moving average price of $4.21 and a 200 day moving average price of $4.05. The company has a market cap of $372.55 million, a P/E ratio of -4.95 and a beta of 0.42. Corvus Pharmaceuticals has a 1 year low of $2.54 and a 1 year high of $10.00.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals 的股票在星期四以 5.00 美元开盘。该股票的 50 日移动平均价格为 4.21 美元，200 日移动平均价格为 4.05 美元。该公司的市值为 3.7255 亿美元，市盈率为 -4.95，贝塔值为 0.42。Corvus Pharmaceuticals 的一年低点为 2.54 美元，一年高点为 10.00 美元。</p>
</div><p>Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.03.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals（纳斯达克代码：CRVS - 获取免费报告）最近在 8 月 7 日星期四公布了季度收益数据。该公司报告的每股收益（EPS）为（$0.10），超过了市场普遍预期的（$0.13）3 美分。</p>
</div><h2>Insider Buying and Selling at Corvus Pharmaceuticals</h2>
<div class="lb-trans"><h2>Corvus Pharmaceuticals 的内部买卖</h2>
</div><p>In other news, Director Peter A. Thompson sold 1,176,332 shares of the firm's stock in a transaction dated Friday, June 27th. The stock was sold at an average price of $4.16, for a total transaction of $4,893,541.12. Following the completion of the sale, the director directly owned 7,165,006 shares of the company's stock, valued at $29,806,424.96. This trade represents a 14.10% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this hyperlink. 28.50% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Peter A. Thompson 于 6 月 27 日星期五出售了 1,176,332 股该公司的股票。该股票以平均价格 4.16 美元出售，总交易额为 4,893,541.12 美元。出售完成后，该董事直接持有该公司 7,165,006 股股票，价值 29,806,424.96 美元。此交易代表其持股减少了 14.10%。该交易已在向证券交易委员会提交的文件中披露，文件可在此链接查看。28.50% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of hedge funds have recently made changes to their positions in CRVS. Sowell Financial Services LLC acquired a new position in shares of Corvus Pharmaceuticals during the 1st quarter valued at about $38,000. Virtus ETF Advisers LLC acquired a new position in shares of Corvus Pharmaceuticals during the 4th quarter valued at about $47,000. Police &amp; Firemen s Retirement System of New Jersey acquired a new stake in Corvus Pharmaceuticals in the 2nd quarter valued at approximately $49,000. ProShare Advisors LLC acquired a new stake in Corvus Pharmaceuticals in the 2nd quarter valued at approximately $54,000. Finally, Alpine Global Management LLC acquired a new stake in Corvus Pharmaceuticals in the 4th quarter valued at approximately $62,000. Institutional investors and hedge funds own 46.64% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金最近对 CRVS 的持仓进行了调整。Sowell Financial Services LLC 在第一季度以约 38,000 美元的价格收购了 Corvus Pharmaceuticals 的新股份。Virtus ETF Advisers LLC 在第四季度以约 47,000 美元的价格收购了 Corvus Pharmaceuticals 的新股份。新泽西州警察和消防员退休系统在第二季度以约 49,000 美元的价格收购了 Corvus Pharmaceuticals 的新股份。ProShare Advisors LLC 在第二季度以约 54,000 美元的价格收购了 Corvus Pharmaceuticals 的新股份。最后，Alpine Global Management LLC 在第四季度以约 62,000 美元的价格收购了 Corvus Pharmaceuticals 的新股份。机构投资者和对冲基金持有该公司 46.64% 的股票。</p>
</div><h2>Corvus Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Corvus Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司，专注于开发和商业化免疫调节剂产品候选药物，以治疗实体癌症、T 细胞淋巴瘤、自身免疫、过敏和传染病。其主要产品候选药物是 soquelitinib（CPI-818），这是一种选择性共价抑制剂，针对白细胞介素 2 诱导的 T 细胞激酶（ITK），目前正在进行多中心的 1/1b 期临床试验，以治疗外周 T 细胞淋巴瘤、实体肿瘤和特应性皮炎。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Corvus Pharmaceuticals</li>
<li>TSX Venture Exchange (Formerly Canadian Venture Exchange)</li>
<li>Data Centers Create a Bull Case for These Nuclear 3 Stocks</li>
<li>Manufacturing Stocks Investing</li>
<li>Tesla’s Pennant Just Snapped: Here’s What It Means for the Stock</li>
<li>Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?</li>
<li>3 Companies That Will Profit From Trump's Semiconductor Tariffs</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Corvus Pharmaceuticals</li>
<li>TSX 风险投资交易所（前称加拿大风险投资交易所）</li>
<li>数据中心为这三只核能股票创造了牛市案例</li>
<li>制造业股票投资</li>
<li>特斯拉的旗帜刚刚断裂：这对股票意味着什么</li>
<li>房地产投资信托是否值得在您的投资组合中占有一席之地？</li>
<li>三家公司将从特朗普的半导体关税中获利</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=CRVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Corvus Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Corvus Pharmaceuticals 吗？</h2>
</div><p>Before you consider Corvus Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑投资 Corvus Pharmaceuticals 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Corvus Pharmaceuticals 并不在名单上。</p>
</div><p>While Corvus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Corvus Pharmaceuticals 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HC Wainwright 对 Corvus Pharma 第三季度收益的预测是什么？